醋酸戈舍瑞林缓释植入剂治疗前列腺癌的临床疗效及对患者细胞炎症反应因子的影响
|
摘要
目的:观察醋酸戈舍瑞林缓释植入剂治疗前列腺癌的临床疗效及对患者细胞炎症反应因子的影响。方法:选取2015年12月至2017年12月到我院治疗的前列腺癌患者68例,随机分为两组,对照组患者应用比卡鲁胺治疗,研究组患者在应用比卡鲁胺的基础上联合醋酸戈舍瑞林缓释植入剂治疗。结果:各组治疗有效率对比,研究组患者有效率显著高于对照组(P <0. 05);治疗前两组患者的细胞炎症反应因子水平无明显区别(P> 0. 05),治疗后研究组患者白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均显著低于对照组(P <0. 05),白介素-10(IL-10)水平显著高于对照组(P <0. 05);研究组患者腹泻、乳房胀痛、乏力等不良反应发生率均显著低于对照组(P <0. 05);治疗前两组患者的α-甲酰基辅酶A消旋酶(P504S)、血清前列腺特异抗原(PSA)水平无明显区别(P> 0. 05),治疗后研究组患者P504S、血清PSA水平均显著低于对照组(P<0. 05)。结论:在前列腺癌的治疗过程当中,醋酸戈舍瑞林缓释植入剂对前列腺癌患者的治疗效果理想,能够使患者的细胞炎性反应得到减轻,安全性较高,因此临床上应当进一步的推广与应用。
Objective: To observe the clinical efficacy of goserelin acetate sustained-release depot in the treatment of prostate cancer and its influence on cellular inflammatory response factors. Methods: 68 cases of prostate cancer from December,2015 to December,2017 in our hospital were randomly divided into two groups. The control group was treated with basteramine,and the patients in the study group were treated with goserelin acetate sustained-release depot on the basis of the application of basteramine. Results: The effective rate of research group was significantly higher than that of the control group( P < 0. 05),and there was no significant difference in inflammation factors between the two groups before treatment( P > 0. 05). The indexes of IL-6 and TNF-alpha in the research group after treatment were significantly lower than those in the control group( P < 0. 05),and the IL-10 index was significantly higher than that of the control group( P < 0. 05). The incidence of diarrhoea,breast distention and fatigue in the research group was significantly lower than that of the control group( P < 0. 05). There was no significant difference in the level of P504 S and serum PSA in the two groups before the treatment( P > 0. 05). The P5 0 4 S level and the serum PSA level index of the patients in the research group were significantly lower than those in the control group( P< 0. 05). Conclusion: In the course of the treatment of prostate cancer,the treatment effect of goserelin acetate sustained-release depot to the prostate cancer patients is ideal. It can reduce the inflammatory response of the patients and has high safety. Therefore,it should be further popularized and applied in the clinic.
Objective: To observe the clinical efficacy of goserelin acetate sustained-release depot in the treatment of prostate cancer and its influence on cellular inflammatory response factors. Methods: 68 cases of prostate cancer from December,2015 to December,2017 in our hospital were randomly divided into two groups. The control group was treated with basteramine,and the patients in the study group were treated with goserelin acetate sustained-release depot on the basis of the application of basteramine. Results: The effective rate of research group was significantly higher than that of the control group( P < 0. 05),and there was no significant difference in inflammation factors between the two groups before treatment( P > 0. 05). The indexes of IL-6 and TNF-alpha in the research group after treatment were significantly lower than those in the control group( P < 0. 05),and the IL-10 index was significantly higher than that of the control group( P < 0. 05). The incidence of diarrhoea,breast distention and fatigue in the research group was significantly lower than that of the control group( P < 0. 05). There was no significant difference in the level of P504 S and serum PSA in the two groups before the treatment( P > 0. 05). The P5 0 4 S level and the serum PSA level index of the patients in the research group were significantly lower than those in the control group( P< 0. 05). Conclusion: In the course of the treatment of prostate cancer,the treatment effect of goserelin acetate sustained-release depot to the prostate cancer patients is ideal. It can reduce the inflammatory response of the patients and has high safety. Therefore,it should be further popularized and applied in the clinic.
引文
[1]Li Yong,Xu Zhigang,Zhang Xiaoping,et al.Docetaxel plus prednisone in the treatment of steroid resistant prostate cancer[J].Tumor Medicine,2017,36(6):436-437.[李勇,徐志刚,张小平,等.多西紫杉醇联合泼尼松治疗激素抵抗性前列腺癌的疗效分析[J].肿瘤药学,2017,36(6):436-437.]
[2]Boccardo F,Rubagotti A,Battaglia M,et al.Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer[J].J Clin Oncol,2016,23(4):808-815.
[3]van Leeuwen PJ,Stricker P,Hruby G,et al.(68)Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment[J].Bju International,2016,195(4):e987.
[4]Cha YJ,Lee JH,Han HH,et al.MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer:STAT3 and ZEB1 are upregulated during prostate carcinogenesis[J].Prostate,2016,76(10):937-947.
[5]Leidinger P,Hart M,Backes C,et al.Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer:miRNA as source for biomarkers independent of PSA level,Gleason score,or TNM status[J].Tumor Biology,2016,37(8):10177-10185.
[6]Shariat SF,Karakiewicz PI,Suardi N,et al.Comparison of nomograms with other methods for predicting outcomes in prostate cancer:A critical analysis of the literature[J].Clinical Cancer Research,2016,14(14):4400-4407.
[7]Shen Lixian,Zhou Bin,Li Haiyan,et al.Research progress in signal transduction pathways related to prostate cancer development and development[J].Cancer Medicine,2016,6(2):96-102.[申利贤,周斌,李海艳,等.前列腺癌发生发展相关信号转导通路的研究进展[J].肿瘤药学,2016,6(2):96-102.]
[8]James ND,Sydes MR,Clarke NW,et al.Addition of docetaxel,zoledronic acid,or both to first-line long-term hormone therapy in prostate cancer(STAMPEDE):Survival results from an adaptive,multiarm,multistage,platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
[9]Budus L,Leyh-Bannurah SR,Salomon G,et al.Initial experience of68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy[J].European Urology,2016,69(3):393-396.
[10]Suardi N,Gandaglia G,Gallina A,et al.Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer:Results of a single-institution series with a minimum follow-up of 5 years[J].European Urology,2016,34(5):763-764.
[11]Cornford P,Bellmunt J,Bolla M,et al.EAU guidelines on prostate cancer.Part II:Treatment of relapsing,metastatic,and castrationresistant prostate cancer[J].European Urology,2016,35(10):565-568.
[12]Ahmed HU,Bosaily ES,Brown LC,et al.Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS):A paired validating confirmatory study[J].Lancet,2017,389(10071):815-822.
[13]Gillessen S,Attard G,Beer TM,et al.Management of patients with advanced prostate cancer:The report of the advanced prostate cancer consensus conference APCCC 2017[J].European Urology,2017,73(2)645-647.
[14]Kumar A,Coleman I,Morrissey C,et al.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer[J].Nature Medicine,2016,22(4):369-378.
[2]Boccardo F,Rubagotti A,Battaglia M,et al.Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer[J].J Clin Oncol,2016,23(4):808-815.
[3]van Leeuwen PJ,Stricker P,Hruby G,et al.(68)Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment[J].Bju International,2016,195(4):e987.
[4]Cha YJ,Lee JH,Han HH,et al.MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer:STAT3 and ZEB1 are upregulated during prostate carcinogenesis[J].Prostate,2016,76(10):937-947.
[5]Leidinger P,Hart M,Backes C,et al.Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer:miRNA as source for biomarkers independent of PSA level,Gleason score,or TNM status[J].Tumor Biology,2016,37(8):10177-10185.
[6]Shariat SF,Karakiewicz PI,Suardi N,et al.Comparison of nomograms with other methods for predicting outcomes in prostate cancer:A critical analysis of the literature[J].Clinical Cancer Research,2016,14(14):4400-4407.
[7]Shen Lixian,Zhou Bin,Li Haiyan,et al.Research progress in signal transduction pathways related to prostate cancer development and development[J].Cancer Medicine,2016,6(2):96-102.[申利贤,周斌,李海艳,等.前列腺癌发生发展相关信号转导通路的研究进展[J].肿瘤药学,2016,6(2):96-102.]
[8]James ND,Sydes MR,Clarke NW,et al.Addition of docetaxel,zoledronic acid,or both to first-line long-term hormone therapy in prostate cancer(STAMPEDE):Survival results from an adaptive,multiarm,multistage,platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
[9]Budus L,Leyh-Bannurah SR,Salomon G,et al.Initial experience of68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy[J].European Urology,2016,69(3):393-396.
[10]Suardi N,Gandaglia G,Gallina A,et al.Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer:Results of a single-institution series with a minimum follow-up of 5 years[J].European Urology,2016,34(5):763-764.
[11]Cornford P,Bellmunt J,Bolla M,et al.EAU guidelines on prostate cancer.Part II:Treatment of relapsing,metastatic,and castrationresistant prostate cancer[J].European Urology,2016,35(10):565-568.
[12]Ahmed HU,Bosaily ES,Brown LC,et al.Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS):A paired validating confirmatory study[J].Lancet,2017,389(10071):815-822.
[13]Gillessen S,Attard G,Beer TM,et al.Management of patients with advanced prostate cancer:The report of the advanced prostate cancer consensus conference APCCC 2017[J].European Urology,2017,73(2)645-647.
[14]Kumar A,Coleman I,Morrissey C,et al.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer[J].Nature Medicine,2016,22(4):369-378.